Key result
Black HFrEF patients have ~100% higher odds of reaching target ACEi/ARB/ARNi doses than White patients.
Why the study?
Does guideline-directed medical therapy use and target dosing differ between Black and White patients with HFrEF?
Population
2,825 patients with heart failure with reduced ejection fraction, 61.2% Black and 38.8% White, from a large…
Comparison
Black race (observational exposure) vs White race
Design
Cohort
Authors
Loading...
Higher target dosing in Black patients should not yet change practice; leaves open generalizability beyond this integrated system.
Cohort (n=2,825)
Does guideline-directed medical therapy use and target dosing differ between Black and White patients with HFrEF?
Odds Ratio: 2 (95% CI 1.61–2.53)
Absolute Event Rate: 45.2% vs 34.2%
In a large integrated health system, Black patients with HFrEF were more likely to receive certain guideline-directed medical therapies and achieve target doses compared to White patients.
Berry et al. (2026) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=2,825). Black race vs. White race was evaluated on Treatment to target dose with ACEi/ARB/ARNi among treated patients (OR 2.0, 95% CI 1.61-2.53). Black patients with HFrEF had greater odds of being treated to target with ACEi/ARB/ARNi (OR 2.0; 95% CI 1.61-2.53) and MRAs (OR 1.6; 95% CI 1.01-2.57) compared to White patients.
Synapse has enriched one closely related paper. Consider it for comparative context: